Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database
暂无分享,去创建一个
B. Bonanni | P. Møller | E. Hovig | D. Evans | G. Capellá | J. Mecklin | W. Schmiegel | C. Engel | N. Gluck | M. Mints | J. Sampson | F. Lalloo | I. Winship | S. Aretz | F. Macrae | R. Sijmons | M. Nielsen | G. Cavestro | E. Crosbie | D. Vangala | M. Tibiletti | L. Bertario | J. Plazzer | K. Heinimann | M. Navarro | L. Katz | M. Pineda | H. Thomas | K. Green | T. Seppälä | James O. Hill | C. Vaccaro | C. Perne | G. Rosner | M. Dominguez-Valentin | Verena Steinke-Lange | H. Strauss | N. Ryan | M. L. González | T. Piñero | P. Kalfayan | R. Kariv | E. Holinski-Feder | J. B. Vidal | Johanna Tecklenburg | H. Strauß | J. Hill | V. Steinke-Lange | J. Hill | D. Evans | James O. Hill | D. Evans
[1] D. Evans,et al. A mismatch in care: results of a United Kingdom‐wide patient and clinician survey of gynaecological services for women with Lynch syndrome , 2020, BJOG : an international journal of obstetrics and gynaecology.
[2] R. Manchanda,et al. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. , 2020, Best practice & research. Clinical obstetrics & gynaecology.
[3] J. Pinkerton. Hormone Therapy for Postmenopausal Women. , 2020, The New England journal of medicine.
[4] S. Houterman,et al. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. , 2019, The Cochrane database of systematic reviews.
[5] Aung Ko Win,et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database , 2019, Genetics in Medicine.
[6] P. Møller,et al. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome , 2019, Genetics in Medicine.
[7] A. Bats,et al. Prophylactic hysterectomy in Lynch syndrome: Feasibility and outcomes , 2019, European Journal of Obstetrics & Gynecology and Reproductive Biology.
[8] M. Dwyer,et al. Genetic/Familial high-risk assessment: Colorectal, version 2.2019 featured updates to the NCCN guidelines , 2019 .
[9] Aung Ko Win,et al. Cancer Risks for PMS2-Associated Lynch Syndrome. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Crosbie,et al. Recognizing Gynecological Cancer in Primary Care: Risk Factors, Red Flags, and Referrals , 2018, Advances in Therapy.
[11] D. Evans,et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome , 2017, JAMA oncology.
[12] P. Møller,et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.
[13] P. Møller,et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.
[14] W. Rocca,et al. Long-term health consequences of premature or early menopause and considerations for management , 2015, Climacteric : the journal of the International Menopause Society.
[15] E. Giovannucci,et al. The effect of estrogen vs. combined estrogen‐progestogen therapy on the risk of colorectal cancer , 2012, International journal of cancer.
[16] D. Winter,et al. Oestrogen and the colon: potential mechanisms for cancer prevention. , 2008, The Lancet. Oncology.
[17] M. Munsell,et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. , 2006, The New England journal of medicine.
[18] Heidi D Nelson,et al. Postmenopausal hormone replacement therapy: scientific review. , 2002, JAMA.
[19] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[20] L. Aaltonen,et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. , 2000, Gastroenterology.
[21] S. Shapiro,et al. A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[22] F. Grodstein,et al. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. , 1999, The American journal of medicine.
[23] V. Hasselblad,et al. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis , 1998, Obstetrics and gynecology.
[24] R. Nelson,et al. Colorectal , 1994, Current opinion in general surgery.